Takeda’s Koo to lead Overland-ADC joint venture; plus Precision, Amryt, Bridge, Opthea and Cogent
Eric Koo will become CEO of Overland ADCT BioPharma (CY) Ltd., the joint venture between Overland Pharmaceuticals and ADC Therapeutics S.A. (NYSE:ADCT) that launched in December. The JV is developing ADC Therapeutics’ loncastuximab tesirine, a pyrrolobenzodiazepine (PBD) dimer-linked humanized mAb against CD19 that is under FDA review, and three other PBD-based antibody-drug conjugates in Greater China and Singapore. Koo has experience at a quartet of MNCs, most recently Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK), where he was VP, head of oncology business unit at Takeda China.
Precision BioSciences Inc. (NASDAQ:DTIL) is looking for a CEO to succeed co-founder Matt Kane in what the company is calling its next “phase of growth.” Kane is expected to remain with the company until his replacement is found and as an adviser during a transition period. Precision shares fell 12% to $9.23 on Tuesday...